An evaluation of the association between C-reactive protein, the change in C-reactive protein over one year, and all-cause mortality in chronic immune-mediated inflammatory disease managed in UK general practice

Rheumatology

Volumn 48, Issue 1, 2009, Pages 78-82

  Poole, C D ^a   Conway, P ^b   Currie, C J ^c  

^a UNIVERSITY HOSPITAL OF WALES   (United Kingdom)

^b Wyeth Europa Limited   (United Kingdom)

^c CARDIFF UNIVERSITY   (United Kingdom)

Author keywords

Ankylosing spondylitis; C reactive protein; Psoriasis; Psoriatic arthritis; Rheumatoid arthritis; Survival; Systemic inflammation

Indexed keywords

C REACTIVE PROTEIN;

ADULT; ANKYLOSING SPONDYLITIS; ARTICLE; CARDIOVASCULAR RISK; CHRONIC INFLAMMATION; COHORT ANALYSIS; CONTROLLED STUDY; FEMALE; GENERAL PRACTICE; HUMAN; IMMUNOPATHOLOGY; MAJOR CLINICAL STUDY; MALE; MORTALITY; PRIORITY JOURNAL; PROGNOSIS; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; PSORIASIS; PSORIATIC ARTHRITIS; RHEUMATOID ARTHRITIS; STANDARDIZATION; SURVIVAL; UNITED KINGDOM;

ADULT; AGED; ARTHRITIS; ARTHRITIS, RHEUMATOID; AUTOIMMUNE DISEASES; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; CHRONIC DISEASE; COHORT STUDIES; FEMALE; GREAT BRITAIN; HUMANS; INFLAMMATION; MALE; MIDDLE AGED; PSORIASIS; SURVIVAL ANALYSIS;

EID: 57349186493     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/ken415     Document Type: Article

References (34)

1. Scirica BM, Morrow DA. Is C-reactive protein an innocent bystander or proatherogenic culprit? The verdict is still out. Circulation 2006;113:2128-34.
2. Nilsson J. CRP: Marker or maker of cardiovascular disease? Arterioscler Thromb Vasc Biol 2005;25:1527-8.
3. Verma S, Devaraj S, Jialal I. C-reactive protein promotes atherothrombosis. Circulation 2006;113:2135-50.
4. Bisoendial RJ, Kastelein JJ, Levels JH et al. Activation of inflammation and coagulation after infusion of C-reactive protein in humans. Circ Res 2005;96:714-6.
5. Abou-Raya A, Abou-Raya S. Inflammation: A pivotal link between autoimmune diseases and atherosclerosis. Autoimmun Rev 2006;5:331-7.
6. Han C, Robinson DW Jr, Hackett MV et al. Cardiovascular disease and risk factors in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis. J Rheumatol 2006;33:2167-72.
7. Shadick NA, Cook NR, Karlson EW et al. C-reactive protein in the prediction of rheumatoid arthritis in women. Arch Intern Med 2006;166:2490-4.
8. Kameda H, Sekiguchi N, Nagasawa H et al. Development and validation of handy rheumatoid activity score with 38 joints (HRAS38) in rheumatoid arthritis patients receiving infliximab. Mod Rheumatol 2006;16:381-8.
9. Soubrier M, Zerkak D, Gossec L, Ayral X, Roux C, Dougados M. Which variables best predict change in rheumatoid arthritis therapy in daily clinical practice? J Rheumatol 2006;33:1243-6.
10. Moreland LW, Weinblatt ME, Keystone EC et al. Etanercept treatment in adults with established rheumatoid arthritis: 7 years of clinical experience. J Rheumatol 2006;33:854-61.
11. Dessein PH, Joffe BI, Singh S. Biomarkers of endothelial dysfunction, cardiovascular risk factors and atherosclerosis in rheumatoid arthritis. Arthritis Res Ther 2005;7: R634-43.
12. Pahor A, Hojs R, Gorenjak M, Rozman B. Accelerated atherosclerosis in pre-menopausal female patients with rheumatoid arthritis. Rheumatol Int 2006;27:119-23.
13. Georgiadis AN, Papavasiliou EC, Lourida ES et al. Atherogenic lipid profile is a feature characteristic of patients with early rheumatoid arthritis: Effect of early treatment - a prospective, controlled study. Arthritis Res Ther 2006;8:R82.
14. Wakkee M, Thio HB, Prens EP, Sijbrands EJG, Neumanna HAM. Unfavorable cardiovascular risk profiles in untreated and treated psoriasis patients. Atherosclerosis 2007;190:1-9.
15. Gelfand JM, Neimann AL, Shin DB, Wang X, Margolis DJ, Troxel AB. Risk of myocardial infarction in patients with psoriasis. J Am Med Assoc 2006;296:1735-41.
16. Kimhi O, Caspi D, Bornstein NM et al. Prevalence and risk factors of atherosclerosis in patients with psoriatic arthritis. Semin Arthritis Rheum 2007;36:203-9.
17. Sari I, Okan T, Akar S et al. Impaired endothelial function in patients with ankylosing spondylitis. Rheumatology 2006;45:283-6.
18. Divecha H, Sattar N, Rumley A et al. Cardiovascular risk parameters in men with ankylosing spondylitis in comparison with non-inflammatory control subjects: Relevance of systemic inflammation. Clin Sci 2005;109:171-6.
19. Zhang L, Astor B, Parekh R et al. Longitudinal relationship of serum albumin and C-reactive protein (CRP) with risk of cardiovascular disease (CVD) and all-cause mortality in a dialysis cohort. Circulation 2006;113:E336-7.
20. Poole CD, Conway P, Currie CJ. An evaluation of the association between the first observation and the longitudinal change in C-reactive protein, and all-cause mortality. Heart 2008;94:457-62.
21. Gonzalez A, Kremers HM, Crowson CS et al. The widening mortality gap between rheumatoid arthritis patients and the general population. Arthritis Rheum 2007; 56:3583-7.
22. Peters MJ, Van Der Horst-Bruinsma IE, Dijkmans BA, Nurmohamed MT. Cardiovascular risk profile of patients with spondylarthropathies, particularly ankylosing spondylitis and psoriatic arthritis. Semin Arthritis Rheum 2004;34: 585-92.
23. Boonen A, Van Der Linden SM. The burden of ankylosing spondylitis. J Rheumatol 2006;33(Suppl. 78):4-11.
24. Gelfand JM, Troxel AB, Lewis JD et al. The risk of mortality in patients with psoriasis: Results from a population-based study. Arch Dermatol 2007;143:1493-9.
25. THIN. http://www.epic-uk.org/thin.htm (17 September 2007, date last accessed).
26. GPRD. http://www.gprd.com/home/ (17 September 2007, date last accessed).
27. Pearson TA, Mensah GA, Alexander WR. Markers of inflammation and cardiovascular disease: Application to clinical and public health practice: A statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation 2003;107:499-511.
28. Miller M, Zhan M, Havas S. High attributable risk of elevated C-reactive protein level to conventional coronary heart disease risk factors: The Third National Health and Nutrition Examination Survey. Arch Intern Med 2005;165:2063-8.
29. Sakkinen PA, Macy EM, Callas PW et al. Analytical and biologic variability in measures of hemostasis, fibrinolysis, and inflammation: assessment and implications for epidemiology. Am J Epidemiol 1999;149:261-7.
30. Ockene IS, Matthews CE, Rifai N et al. Variability and classification accuracy of serial high-sensitivity C-reactive protein measurements in healthy adults. Clin Chem 2001;47:444-50.
31. Poole CD, Conway P, Currie CJ. An evaluation of the association between systemic inflammation - as measured by C-reactive protein - and hospital resource use. Curr Med Res Opin 2007;23:2785-92.
32. Ridker PM. C-reactive protein: A simple test to help predict risk of heart attack and stroke. Circulation 2003;108:e81-5.
33. Cushman M, Arnold AM, Psaty BM et al. C-reactive protein and the 10-year incidence of coronary heart disease in older men and women: The cardiovascular health study. Circulation 2005;112:25-31.
34. Pai JK, Pischon T, Ma J et al. Inflammatory markers and the risk of coronary heart disease in men and women. N Engl J Med 2004;351:2599-610.